Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar
Ustekinumab Deal – Which Excludes Certain Asian Markets – Is Worth More Than $100m
• By David Wallace
Meiji and Dong-A take their ustekinumab biosimilar global with Intas • Source: Alamy 
